{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroinflammatory+Disorders&page=5",
    "query": {
      "condition": "Neuroinflammatory Disorders",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 399,
    "total_pages": 40,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroinflammatory+Disorders&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroinflammatory+Disorders&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-17T10:02:10.827Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02466750",
      "title": "Safety and Immunogenicity Study of the Western Equine Encephalitis (WEE) Vaccine",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Western Equine Encephalitis"
      ],
      "interventions": [
        {
          "name": "Western Equine Encephalitis (WEE) Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 500,
      "start_date": "2015-12-15",
      "completion_date": "2021-12",
      "has_results": false,
      "last_update_posted_date": "2021-02-11",
      "last_synced_at": "2026-10-17T10:02:10.827Z",
      "location_count": 1,
      "location_summary": "Fort Deterick, Maryland",
      "locations": [
        {
          "city": "Fort Deterick",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02466750"
    },
    {
      "nct_id": "NCT04636723",
      "title": "Neuroinflammation in Chronic Systemic Symptoms (CSS)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cancer",
        "Cancer Head Neck",
        "Neuroinflammatory Response",
        "Chronic Inflammation",
        "Chronic Disease",
        "Chronic Pain"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2021-02-22",
      "completion_date": "2021-12-07",
      "has_results": false,
      "last_update_posted_date": "2023-01-26",
      "last_synced_at": "2026-10-17T10:02:10.827Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04636723"
    },
    {
      "nct_id": "NCT04201262",
      "title": "An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neuromyelitis Optica",
        "Neuromyelitis Optica Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "Ravulizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 58,
      "start_date": "2019-12-09",
      "completion_date": "2024-10-31",
      "has_results": true,
      "last_update_posted_date": "2025-10-14",
      "last_synced_at": "2026-10-17T10:02:10.827Z",
      "location_count": 10,
      "location_summary": "Aurora, Colorado • Fort Collins, Colorado • Washington D.C., District of Columbia + 7 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04201262"
    },
    {
      "nct_id": "NCT07758270",
      "title": "Brain Imaging and Immune Changes During Remibrutinib Treatment in Multiple Sclerosis.",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis (MS) - Relapsing-remitting"
      ],
      "interventions": [
        {
          "name": "Remibrutinib",
          "type": "DRUG"
        },
        {
          "name": "Ocrelizumab (US)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "40 Years to 70 Years"
      },
      "enrollment_count": 15,
      "start_date": "2026-08-15",
      "completion_date": "2030-08-29",
      "has_results": false,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-10-17T10:02:10.827Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07758270"
    },
    {
      "nct_id": "NCT02166346",
      "title": "Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Transverse Myelitis",
        "Neuromyelitis Optica",
        "Idiopathic Transverse Myelitis",
        "Myelitis NOS"
      ],
      "interventions": [
        {
          "name": "Dalfampridine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 24,
      "start_date": "2014-02",
      "completion_date": "2017-01-08",
      "has_results": true,
      "last_update_posted_date": "2018-04-17",
      "last_synced_at": "2026-10-17T10:02:10.827Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02166346"
    },
    {
      "nct_id": "NCT05491525",
      "title": "Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Neurogenic Detrusor Overactivity"
      ],
      "interventions": [
        {
          "name": "Vibegron",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Urovant Sciences GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 71,
      "start_date": "2022-10-12",
      "completion_date": "2030-09",
      "has_results": false,
      "last_update_posted_date": "2026-06-15",
      "last_synced_at": "2026-10-17T10:02:10.827Z",
      "location_count": 11,
      "location_summary": "Little Rock, Arkansas • Orange, California • Aurora, Colorado + 8 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05491525"
    },
    {
      "nct_id": "NCT00011245",
      "title": "Study and Surgical Treatment of Syringomyelia",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Syringomyelia"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2001-02-08",
      "completion_date": "2011-05-18",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-10-17T10:02:10.827Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00011245"
    },
    {
      "nct_id": "NCT06075732",
      "title": "ACTIVATE in Public Housing",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pneumonia",
        "Influenza",
        "Varicella Zoster",
        "Meningitis",
        "COVID-19",
        "Vaccine Hesitancy"
      ],
      "interventions": [
        {
          "name": "Increasing Willingness and Uptake of Influenza, Pneumonia, Meningitis, HZV, and COVID-19 Vaccination",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Charles Drew University of Medicine and Science",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 400,
      "start_date": "2024-07-01",
      "completion_date": "2024-12-02",
      "has_results": false,
      "last_update_posted_date": "2025-02-17",
      "last_synced_at": "2026-10-17T10:02:10.827Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06075732"
    },
    {
      "nct_id": "NCT03844412",
      "title": "Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Vestibulodynia",
        "Temporomandibular Disorder",
        "Fibromyalgia Syndrome",
        "Irritable Bowel Syndrome",
        "Migraines",
        "Tension Headache",
        "Endometriosis",
        "Interstitial Cystitis",
        "Back Pain",
        "Chronic Fatigue Syndrome"
      ],
      "interventions": [
        {
          "name": "5% lidocaine/5 mg/ml 0.02% estradiol compound cream",
          "type": "DRUG"
        },
        {
          "name": "Nortriptyline",
          "type": "DRUG"
        },
        {
          "name": "Placebo cream",
          "type": "DRUG"
        },
        {
          "name": "Placebo pill",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 209,
      "start_date": "2019-11-04",
      "completion_date": "2024-05-30",
      "has_results": true,
      "last_update_posted_date": "2026-03-19",
      "last_synced_at": "2026-10-17T10:02:10.827Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03844412"
    },
    {
      "nct_id": "NCT00862277",
      "title": "Persistence of Bactericidal Antibodies in Adolescents and Adults Who Had Received a Single Dose of Menactra® Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Meningococcal Infections",
        "Meningitis"
      ],
      "interventions": [
        {
          "name": "Menactra®",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Menomune®",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": "27 Years",
        "sex": "ALL",
        "summary": "14 Years to 27 Years"
      },
      "enrollment_count": 763,
      "start_date": "2008-12",
      "completion_date": "2009-12",
      "has_results": true,
      "last_update_posted_date": "2016-04-14",
      "last_synced_at": "2026-10-17T10:02:10.827Z",
      "location_count": 20,
      "location_summary": "Little Rock, Arkansas • Fountain Valley, California • Marietta, Georgia + 15 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Marietta",
          "state": "Georgia"
        },
        {
          "city": "Martinez",
          "state": "Georgia"
        },
        {
          "city": "Woodstock",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00862277"
    }
  ]
}